The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus

The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Rheumatology 2014-12, Vol.12 (1), p.50-50, Article 50
Main Authors: Bobek, Dubravka, Grčević, Danka, Kovačić, Nataša, Lukić, Ivan Krešimir, Jelušić, Marija
Format: Article
Language:English
Subjects:
Adolescent
alpha-Macroglobulins - metabolism
Anatomy & physiology
Arthritis
Arthritis, Juvenile - diagnosis
Arthritis, Juvenile - metabolism
Biomarkers - metabolism
Blood Sedimentation
C-Reactive Protein - metabolism
Case-Control Studies
Chemokines
Child
Child, Preschool
Disease
Enzymes
Fluid
HMGB1 Protein - metabolism
Hospitals
Humans
Immune system
Immunology
Laboratories
Lupus
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - metabolism
Medicine
Pathogenesis
Pediatrics
Programming languages
Prospective Studies
Receptor for Advanced Glycation End Products
Receptors, Immunologic - metabolism
Rheumatology
Sensitivity and Specificity
Severity of Illness Index
Studies
Synovial Fluid - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.
ISSN:1546-0096
1546-0096
DOI:10.1186/1546-0096-12-50